Seamus Fernandez
Stock Analyst at Guggenheim
(4.01)
# 834
Out of 4,413 analysts
47
Total ratings
53.19%
Success rate
11.03%
Average return
Main Sectors:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALT Altimmune | Downgrades: Neutral | n/a | $6.55 | - | 3 | Apr 29, 2024 | |
| APGE Apogee Therapeutics | Maintains: Buy | $44 → $91 | $50.30 | +80.91% | 3 | Mar 5, 2024 | |
| GSK GSK | Upgrades: Buy | n/a | $41.44 | - | 1 | Mar 4, 2024 | |
| HLVX HilleVax | Maintains: Buy | $38 → $34 | $13.20 | +157.58% | 2 | Nov 15, 2023 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $55 | $6.01 | +815.14% | 1 | Aug 15, 2023 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | n/a | $25.57 | - | 2 | Jul 14, 2023 | |
| MRK Merck & Co. | Maintains: Buy | $123 → $124 | $129.22 | -4.04% | 7 | Apr 11, 2023 | |
| LLY Eli Lilly | Maintains: Buy | $395 → $392 | $781.10 | -49.81% | 4 | Apr 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Buy | $32 | $12.25 | +161.22% | 1 | Mar 7, 2023 | |
| PCVX Vaxcyte | Maintains: Buy | $66 → $65 | $60.55 | +7.35% | 2 | Feb 28, 2023 | |
| GPCR Structure Therapeutics | Initiates: Buy | $50 | $39.44 | +26.77% | 1 | Feb 28, 2023 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | n/a | $43.94 | - | 5 | Oct 10, 2022 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $128.31 | - | 2 | May 31, 2022 | |
| NVS Novartis AG | Downgrades: Neutral | n/a | $97.13 | - | 3 | Feb 25, 2020 | |
| DERM Journey Medical | Downgrades: Neutral | n/a | $3.69 | - | 1 | Feb 3, 2020 | |
| ITCI Intra-Cellular Therapies | Initiates: Outperform | n/a | $71.81 | - | 3 | Nov 15, 2018 | |
| ACRS Aclaris Therapeutics | Maintains: Outperform | n/a | $1.21 | - | 1 | Mar 13, 2018 | |
| CLDX Celldex Therapeutics | Maintains: Market Perform | n/a | $37.42 | - | 1 | Mar 8, 2018 | |
| AZN AstraZeneca | Maintains: Market Perform | n/a | $75.88 | - | 3 | Feb 6, 2018 | |
| PFE Pfizer | Maintains: Market Perform | n/a | $25.62 | - | 1 | Jan 31, 2018 |
Altimmune
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.55
Upside: -
Apogee Therapeutics
Mar 5, 2024
Maintains: Buy
Price Target: $44 → $91
Current: $50.30
Upside: +80.91%
GSK
Mar 4, 2024
Upgrades: Buy
Price Target: n/a
Current: $41.44
Upside: -
HilleVax
Nov 15, 2023
Maintains: Buy
Price Target: $38 → $34
Current: $13.20
Upside: +157.58%
Verve Therapeutics
Aug 15, 2023
Maintains: Buy
Price Target: $56 → $55
Current: $6.01
Upside: +815.14%
Arcturus Therapeutics Holdings
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $25.57
Upside: -
Merck & Co.
Apr 11, 2023
Maintains: Buy
Price Target: $123 → $124
Current: $129.22
Upside: -4.04%
Eli Lilly
Apr 11, 2023
Maintains: Buy
Price Target: $395 → $392
Current: $781.10
Upside: -49.81%
Mineralys Therapeutics
Mar 7, 2023
Initiates: Buy
Price Target: $32
Current: $12.25
Upside: +161.22%
Vaxcyte
Feb 28, 2023
Maintains: Buy
Price Target: $66 → $65
Current: $60.55
Upside: +7.35%
Structure Therapeutics
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $39.44
Upside: +26.77%
Bristol-Myers Squibb Company
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $43.94
Upside: -
Novo Nordisk
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $128.31
Upside: -
Novartis AG
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $97.13
Upside: -
Journey Medical
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.69
Upside: -
Intra-Cellular Therapies
Nov 15, 2018
Initiates: Outperform
Price Target: n/a
Current: $71.81
Upside: -
Aclaris Therapeutics
Mar 13, 2018
Maintains: Outperform
Price Target: n/a
Current: $1.21
Upside: -
Celldex Therapeutics
Mar 8, 2018
Maintains: Market Perform
Price Target: n/a
Current: $37.42
Upside: -
AstraZeneca
Feb 6, 2018
Maintains: Market Perform
Price Target: n/a
Current: $75.88
Upside: -
Pfizer
Jan 31, 2018
Maintains: Market Perform
Price Target: n/a
Current: $25.62
Upside: -